Citizens Stands by Market Outperform on Solid Biosciences After FDA Design Alignment
Citizens has maintained its Market Outperform rating and a $15.00 price target on Solid Biosciences (SLDB) after the company achieved alignment with the U.S. Food and Drug Administration on overall Phase 3 study design for its IMPACT DUCHENNE trial. The firm highlights an upcoming regulatory meeting focused on accelerated approval endpoints and not…